<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216004</url>
  </required_header>
  <id_info>
    <org_study_id>20173</org_study_id>
    <nct_id>NCT04216004</nct_id>
  </id_info>
  <brief_title>Anti-Inflammatory Milk Matrix</brief_title>
  <acronym>AIMM</acronym>
  <official_title>Dairy Food Consumption and Its Effects on Inflammation and the Postprandial Regulation of Muscle Protein Synthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Urbana-Champaign</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Urbana-Champaign</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is pro-inflammatory, impairs metabolism, and physically limiting. Specifically,
      muscle in obese persons does not synthesize proteins normally. This further increases
      metabolic and physical dysfunction. As such, obesity programs should not only focus on weight
      loss, but muscle metabolic health. Dairy nutrients have anti-inflammatory and anabolic
      properties, but mostly evaluated in isolation and/or pre-clinical designs. Also, it is
      unknown if the circulating benefits extend to the muscle. We hypothesize that dairy full-fat
      milk will improve these obesity characteristics.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare fractional synthesis rate of myofibrillar protein to different dairy matrices</measure>
    <time_frame>0-5 hours postprandial observation period to ingesting 2 servings of respective Arm</time_frame>
    <description>Rate of building new proteins in skeletal muscle contractile protein fraction after a meal</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare concentration of inflammation markers in the blood to different dairy matrices</measure>
    <time_frame>1 week observation period to respective Arm within a weight-maintenance diet</time_frame>
    <description>Measurement of blood cytokines, monocytes, and macrophages before and after a diet intervention.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Obesity</condition>
  <condition>Skeletal Muscle</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Full-fat dairy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3x daily servings (cup-eq) of full-fat (3.25%) commercial cow's milk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-fat diary</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3x daily servings (cup-eq) of non-fat (0%) commercial cow's milk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-dairy control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3x daily servings (cup-eq) of non-dairy sourced macronutrient composition of full-fat milk.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Diet-controlled intervention</intervention_name>
    <description>1-week weight-maintenance diet-controlled intervention.</description>
    <arm_group_label>Full-fat dairy</arm_group_label>
    <arm_group_label>Non-dairy control</arm_group_label>
    <arm_group_label>Non-fat diary</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese (BMI, body mass index ≥30, &lt;40 kg•m-2)

          -  Age 40-59

          -  Pre-menopausal

          -  Sedentary/insufficiently active for prior 6 months (mo)

          -  Weight stable for prior 6 mo

        Exclusion Criteria:

          -  Tobacco, nicotine (patch/gum) use (previous 6 mo)

          -  Alcohol consumption &gt;10 drinks per week

          -  Metabolic disorders (e.g., Metabolic Syndrome, Diabetes, thyroid diseases)

          -  Cardiovascular disease, arrhythmias

          -  Hypogonadism

          -  Asthma

          -  History of uncontrolled hypertension

          -  Orthopedic injury/surgery (within 1 yr)

          -  Hepatorenal, musculoskeletal, autoimmune, or neurological disease

          -  History of neuromuscular problems

          -  Previous participation in amino acid tracer studies

          -  Predisposition to hypertrophic scarring or keloid formation

          -  Consumption of ergogenic-levels of dietary supplements that may affect muscle mass
             (e.g., creatine, HMB), insulin-like substances, or anabolic/catabolic pro-hormones
             (e.g., DHEA) within 6 weeks prior to participation

          -  Consumption of thyroid, androgenic, or other medications known to affect endocrine
             function

          -  Consumption of medications known to affect protein metabolism (e.g.,
             prescription-strength corticosteroids, non-steroidal anti-inflammatories, or acne
             medication)

          -  Pregnancy

          -  Allergy to dairy product or lactose intolerance

          -  Fasting plasma glucose (FPG) ≥ 126 mg/dL

          -  Oral glucose tolerance test (OGTT) ≥ 200 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 30, 2019</last_update_submitted>
  <last_update_submitted_qc>December 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Urbana-Champaign</investigator_affiliation>
    <investigator_full_name>Nicholas Burd</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

